Arbutus Biopharma (ABUS) Interest Expenses (2017 - 2026)

Arbutus Biopharma has disclosed Interest Expenses across 10 years of filings, most recently posting $17000.0 for Q1 2026.

• Interest Expenses for Q1 2026 came in at $17000.0, down 39.29% year-over-year; the trailing twelve-month figure through Mar 2026 was $86000.0 (down 28.93% YoY), and the FY2025 annual result was $97000.0, down 29.2% from the prior year.
• Interest Expenses came in at $17000.0 for Q1 2026 at Arbutus Biopharma, down from $18000.0 in the prior quarter.
• In the past five years, Interest Expenses ranged from a high of $506000.0 in Q1 2022 to a low of $17000.0 in Q1 2026.
• The 5-year median for Interest Expenses is $44000.0 (2023), against an average of $143294.1.
• Across the five-year window, Interest Expenses slumped 89.28% in 2023 and declined 17.65% in 2025, its largest moves.
• Arbutus Biopharma's Interest Expenses stood at $309000.0 in 2022, then sank by 85.76% to $44000.0 in 2023, then sank by 31.82% to $30000.0 in 2024, then sank by 40.0% to $18000.0 in 2025, then decreased by 5.56% to $17000.0 in 2026.
• The last three Interest Expenses figures came in at $17000.0 (Q1 2026), $18000.0 (Q4 2025), and $23000.0 (Q3 2025), per Business Quant data.